Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PROCEPT BioRobotics (PRCT) Operating Expenses (2020 - 2025)

Historic Operating Expenses for PROCEPT BioRobotics (PRCT) over the last 6 years, with Q3 2025 value amounting to $77.2 million.

  • PROCEPT BioRobotics' Operating Expenses rose 3009.88% to $77.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $286.1 million, marking a year-over-year increase of 2937.96%. This contributed to the annual value of $233.7 million for FY2024, which is 2968.28% up from last year.
  • According to the latest figures from Q3 2025, PROCEPT BioRobotics' Operating Expenses is $77.2 million, which was up 3009.88% from $73.9 million recorded in Q2 2025.
  • PROCEPT BioRobotics' Operating Expenses' 5-year high stood at $77.2 million during Q3 2025, with a 5-year trough of $14.9 million in Q1 2021.
  • For the 5-year period, PROCEPT BioRobotics' Operating Expenses averaged around $43.4 million, with its median value being $44.1 million (2023).
  • As far as peak fluctuations go, PROCEPT BioRobotics' Operating Expenses skyrocketed by 8979.87% in 2022, and later skyrocketed by 2473.83% in 2024.
  • Quarter analysis of 5 years shows PROCEPT BioRobotics' Operating Expenses stood at $21.3 million in 2021, then skyrocketed by 67.31% to $35.7 million in 2022, then surged by 42.27% to $50.8 million in 2023, then increased by 24.74% to $63.4 million in 2024, then increased by 21.8% to $77.2 million in 2025.
  • Its Operating Expenses was $77.2 million in Q3 2025, compared to $73.9 million in Q2 2025 and $71.6 million in Q1 2025.